eli lilly glp-1 sales performance Expands Capacity While Building Beyond Obesity And Diabetes Eli Lilly Q1 2025 slides:
Description
Insurance coverage for off-label use may be limited, creating significant financial barriers for many patients
GLP-1 inhibitors are injectable medications originally developed to treat type 2 diabetes
It is not a substitute for advice from physicians or other health care providers
Without the natural stimulation to eat or drink, the dose will likely need to be decreased (I have done this several times with my patients)
However, it is noteworthy that a considerable number of our clients have experienced weight loss of up to 10% of their body weight within a three-month timeframe
4A Make sure a needle is attached and the dose is set to "0." 4B Turn the dose selector until the dose pointer lines up with your dose
